• Muhammad Talal khan Bakhtawar Amin Medical and Dental Collage
  • Afsheen Mansoor Islamic International Dental Collage
  • Aleena Hussain Islamabad Medical and Dental College
  • Muhammad Waqar Hussain Bakhtawar Amin Medical and Dental Collage
  • Farrukh Ahmad Bakhtawar Amin Medical and Dental Collage
  • Emaan Mansoor Islamic international dental college, Riphah International University
Keywords: Bacillus Calmette-Guerin vaccine (BCG), ARS-COV-2, Tuberculosis, Coronavirus, COVID-19


Background: Bacillus Calmette-Guerin (BCG) vaccine is weakened Mycobacterium bovis based preparation that provides protective effects and immunotherapy against many ailments and may be tested against SARS-COV-2. Herein, we compare the prevalence of COVID-19 in countries with and without mandatory BCG vaccination program along with a study to examine its incidence in doctors working at quarantine facility with and without history of prior BCG vaccination. Methods: For cross-sectional examination, the data was collated from worldometer.info, BCG World Atlas and COVID-19 stats at National Command and Operation Centre (NCOC), Government of Pakistan accessed on Apr 30, 2021. For a real-time analysis, total of one hundred random male and female doctors working at a COVID-19 healthcare facility in Pakistan were voluntarily selected. Chi-square test was used to perform the statistical analysis with the help of SPSS-22. Results: The prevalence of COVID-19 in countries with and without a mandatory BCG vaccination policy was found to be 5,512 and 75,592 cases per million, respectively, and mortality rates were 98 and 1,435 per million, respectively. Amongst our randomly selected doctors, only 28% of the BCG vaccinated doctors were affected by COVID-19 contrary to 94% of those who were unvaccinated. Conclusions: The incidence of COVID-19 was considerably lower in the doctors with a history of BCG vaccination supported by the evidence that the countries with a universal BCG vaccine policy had a significantly low incidence and lower mortality rate due to COVID-19.


Bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics 2014;133:e73–81.

de Castro MJ, Pardo-Seco J, Martinon-Torres F. Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory infection and Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Sepsis. Clin Infect Dis. 2015;60:1611–9.

Jensen KJ, Larsen N, Biering-Sorensen S, Andersen A, Eriksen HB, Monteiro I, et al. Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-control trial. J Infect Dis 2015;211:956–67.

Wardhana, Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute respiratory tract infection in the elderly. Acta Med Indones. 2011;43(3):185–90.

Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 2019;25:1473–8.

Yamazaki-Nakashimada MA, Unzueta A, Berenise Gamez-Gonzalez L, Gonzalez-Saldana N, Sorensen RU. BCG: a vaccine with multiple faces. Hum Vaccin Immunother. 2020;6(8):1841–50.

Netea MG, Quintin J, Van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355–61.

Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG Vaccine for COVID-19: First Verdict and Future Directions. Front Immunol. 2021; 12: 632478.

Urashima M, Otani K, Hasegawa Y, Akutsu T. BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study. Int J Environ Res Public Health. 2020; 17(15): 5589.

Li WX. Worldwide inverse correlation between Bacille Calmette-Guérin (BCG) immunization and COVID-19 mortality. Infection. 2021 Jan 25:1–11.

Mohamed Hussein AAR, Salem MR, Salman S, et al. Correlation between COVID-19 case fatality rate and percentage of BCG vaccination: is it true the vaccine is protective?. The Egyptian Journal of Bronchology. 2020; 14(1): 25.

Camila C, Fernandez-Fierro A, Retamal-Diaz A, Diaz FE, Vasquez AE., Lay MK. et al. BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. Front Immunol 2019; 10: 2806.

Covián C, Retamal-Díaz A, Bueno SM, Kalergis AM. Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?. Front Immunol. 2020; 11: 970.

Kowalewicz-Kulbat M, Locht C. BCG and protection against inflammatory and autoimmune diseases. Expert Rev Vaccines. 2017;16(7):1–10.

Clinical trials of BCG for COVID-19; NIH – Clinical Trials. US National Institute of Health. Retrieved April 30, 2020 . https://clinicaltrials.gov/ct2/show/NCT04327206.

Fu W, Ho PC, Liu CL, Tzeng KT, Nayeem N, Moore JS, Wang LS, Chou SY. Reconcile the debate over protective effects of BCG vaccine against COVID-19. Sci Rep. 2021; 11(1): 8356.

Garzon-Chavez D, Rivas-Condo J, Echeverria A, Mozo J, Quentin E, Reyes J, Teran E. COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population. Vaccines (Basel). 2021; 9(2): 91.

Marzoog BA, Vlasova TI. The possible puzzles of BCG vaccine in protection against COVID-19 infection. The Egyptian Journal of Bronchology. 2021; 15(1): 7.

Angelidou A, Diray-Arce J, Conti MG, Smolen KK, van Haren SD, Dowling DJ, et al. BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny. Front Microbiol. 2020; 11: 332.

Angelidou A, Conti MG, Diray-Arce J, Benn CS, Shann F, Netea MG, et al. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine. 2020; 38(9): 2229-2240

Bagheri N, Montazeri H. On BCG Vaccine Protection from COVID-19: A Review. SN Compr Clin Med. 2021:1-11.

Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019; 25(12):1473-1478.

Uthayakumar D, Paris S, Chapat L, Freyburger L, Poulet H, De Luca K. Non-specific Effects of Vaccines Illustrated Through the BCG Example: From Observations to Demonstrations. Front Immunol. 2018 ;9 :2869.

Mathurin KS, Martens GW, Kornfeld H, Welsh RM. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol 2009;83:3528–39.

Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts. 2018 May 30;9(1):64-79.

Netea MG, Joosten LA, Latz E, Millas KH, Natoli G, Stunnerberg HG et al. Trained immunity: A program of innate immune memory in health and disease. Science 2016; 352:aaf1098.

Parmar K, Siddiqui A, Nugent K. Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity Am J Med Sci. 2021;S0002-9629(21): 00092-6.

Aaby P, Roth A, Ravn H, Napirina BM, Rodrigues A, Lisse IM et al. Randomized Trial of BCG Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific effects in the Neonatal Period? J Infect Dis 2011; 204: 245–52.


Download data is not yet available.
How to Cite
khan MT, Mansoor A, Hussain A, Hussain MW, Ahmad F, Mansoor E. EFFECTIVENESS OF BCG VACCINATION AGAINST SARS-COV-2. PJP [Internet]. 30Sep.2021 [cited 18Jan.2022];17(3):40-4. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/1370

Most read articles by the same author(s)